androgens + anabolics

updated

androgens are not peptides. this page compares the depth and limits of their evidence, not what a person should take.

this class cannot be ranked by folklore potency ratios or one borrowed half-life. ester, route, oil vehicle, suspension, oral design, population, and endpoint change the record. testosterone is the clinical reference; oxandrolone, oxymetholone, and nandrolone have substantial but indication-specific human files; several others rely on old, foreign, veterinary, or animal evidence.

no randomized human body-composition head-to-head of two androgen compounds was located. every comparison here is therefore a cross-trial evidence map, not head-to-head proof. S-tier means a deeper documented record. it does not mean low risk, current availability, or suitability for nonmedical use.

human evidence exists, with formulation and indication attached.

the strongest files in this lane also contain direct hepatic, lipid, endocrine, reproductive, hematologic, and cardiovascular warnings.

  • testosterone (tier S) · the clinically characterized reference androgen with approved products, extensive human PK, and a large safety literature. · testosterone supplies the class reference, not a default comparator dose or a safety guarantee. formulation and ester change the exposure curve, and approved indications do not validate nonmedical body-composition use.
  • oxandrolone (anavar) (tier S) · oral 17-alpha-alkylated androgen with measured human PK and controlled burn outcomes; US approvals withdrawn in 2023. · FDA's withdrawal followed safety and effectiveness review. the historical label documents boxed hepatic and lipid risks plus virilization, gonadal suppression, edema, and pediatric growth-plate concerns. evidence depth is not a low-risk verdict.
  • oxymetholone (anadrol) (tier S) · oral anemia drug with controlled human anabolic outcomes and severe dose-related hepatic and lipid harm. · the US NDA remains legally approved while listed products are discontinued. trials reported lean-mass or weight outcomes alongside marked transaminase elevations and jaundice. no validated human terminal half-life was located.
  • nandrolone (tier A) · 19-nor androgen with formulation-specific human PK and a current Australian nandrolone decanoate authorization. · decanoate and phenylpropionate do not share one curve. ester, oil volume, and injection site changed absorption in human studies. the same record documents the need to keep suppression, fertility, virilization, blood, edema, and cardiovascular risks visible.

a studied or marketed compound is not a modern approval or safety file.

these records range from short nonsteroidal-SARM trials and small historical oncology series to current foreign labels, veterinary depot PK, and research-chemical evidence. none may borrow another compound's outcome, half-life, or safety margin.

  • drostanolone (masteron) (tier B) · historical dromostanolone propionate oncology drug with small human series and no validated systemic half-life. · the historical breast-cancer record establishes human exposure and documented virilization. it does not provide a modern controlled cardiovascular, endocrine, reproductive, or formulation PK program.
  • methenolone (primobolan) (tier B) · current Japanese oral acetate medicine with historical injectable enanthate use and no validated systemic half-life for either form. · oral acetate is not 17-alpha-alkylated, but that does not erase virilization, gonadal suppression, fertility, edema, glucose, lipid, liver, or pediatric risks. acetate and enanthate stay separate.
  • methandienone (dianabol) (tier B) · oral 17-alpha-methyl androgen with an old controlled weightlifter trial and US withdrawals for lack of substantial efficacy evidence. · the human trial reported weight and performance changes with likely water contribution, blood-pressure change, frequent adverse effects, and withdrawals. no qualifying systemic human half-life was located.
  • stanozolol (winstrol) (tier B) · 17-alpha-alkylated androgen whose controlled human evidence includes large adverse lipid changes. · the injection is an aqueous suspension of unesterified stanozolol, not a liver-sparing ester. horse suspension PK cannot be assigned to oral humans, and the sponsor-requested US withdrawal notice did not make a safety finding.
  • trenbolone (tier F) · underground injectable androgen with rat body-composition effects and human interview and survey safety signals. · The historical Parabolan record and two oral metabolism studies correct the claim of no human exposure. Interviews and surveys identify aggression, mood, cardiovascular, and hepatic concerns but cannot establish causality, incidence, a safe exposure, or a human depot curve.
  • boldenone (equipoise) (tier F) · veterinary horse drug with equine undecylenate depot PK and no controlled human therapeutic program. · the horse half-life belongs to intramuscular boldenone undecylenate in sesame oil and varied widely. a small human metabolism experiment used oral free boldenone and did not validate the veterinary depot curve.
  • yk-11 (tier F) · steroidal androgen-receptor research chemical with cell and animal studies but no controlled human trial or measured half-life. · a myoblast follistatin signal is not human hypertrophy evidence. animal neurologic findings and mixed-exposure human liver reports justify concern, while the current record cannot define single-ingredient causality or a safe exposure.
  • Enobosarm (tier D) · Enobosarm, also called ostarine or GTx-024, is an unapproved androgen-receptor SARM with short lean-mass signals and split registry-posted phase 3 lean-mass and function results. · Short randomized trials found lean-mass changes in selected older and cancer populations. POWER1 and POWER2 posted split lean-mass and stair-power responder patterns, and the record does not establish durable function, survival, athletic benefit, or long-term safety.
  • Ligandrol (tier C) · Ligandrol, LGD-4033, or VK5211 is an unapproved androgen-receptor SARM with measured human PK, short lean-mass and hormone effects, and delayed registry-only hip-fracture results. · Ligandrol increased DXA lean mass in a short healthy-male study and in delayed sponsor registry results after hip fracture. Neither record established strength, mobility, independence, fewer falls or fractures, bodybuilding performance, fertility safety, or long-term organ safety.

what the evidence can and cannot compare.

which androgen is best for body composition?

the literature does not support that ranking. populations, outcomes, formulations, and study eras differ, and no randomized human body-composition head-to-head of two androgen compounds was located. cross-trial outcomes are not head-to-head evidence. the board grades documentation depth, not personal benefit.

can one androgen's half-life be used for another?

no. free parent, ester, oil vehicle, injection site, depot volume, aqueous suspension, oral formulation, and species all matter. nandrolone decanoate has human depot PK; boldenone and stanozolol values in this dossier are animal and formulation specific; several compounds have no qualifying systemic half-life at all.

does S-tier mean an androgen is safer?

no. S-tier means a deeper, more auditable evidence record. oxandrolone and oxymetholone grade S because they have substantial human and regulatory files, and those same files document severe hepatic and lipid risks. evidence depth can make harm clearer.

which records are current human approvals?

testosterone has current approved products. nandrolone decanoate has a current Australian authorization, and methenolone acetate has a current Japanese label. oxymetholone's US NDA remains legally approved but listed products are discontinued. oxandrolone approvals were withdrawn in 2023. other entries have historical, veterinary, or unapproved status that must be read individually.

is YK-11 just another oral steroid?

it is a steroidal androgen-receptor research chemical, but the usual shortcuts fail. it is not a peptide, not a conventional DHT derivative, and not established as a 17-alpha-alkylated oral androgen. those structural corrections do not supply human efficacy, PK, or safety evidence.

shared class risks, formulation-specific evidence.

what risks recur across androgen records?

hypothalamic-pituitary-gonadal suppression, impaired spermatogenesis and fertility, virilization, erythrocytosis or hematologic change, edema, adverse lipid effects, blood-pressure and cardiovascular concern, and product-specific hepatic risk recur across the class. the magnitude and directness of evidence differ by compound and formulation.

why do the oral 17-alpha-alkylated compounds get separate warnings?

oxandrolone, methandienone, stanozolol, and oxymetholone carry oral designs associated with cholestatic injury and adverse lipid handling. injection does not rescue stanozolol because its injectable form is the same unesterified 17-alpha-alkylated molecule in aqueous suspension.

are injectable androgens liver-safe?

no blanket claim is supported. avoiding a 17-alpha-alkylated oral design changes one risk pathway, not the entire safety profile. endocrine suppression, fertility, virilization, hematologic, edema, cardiovascular, excipient, sterility, concentration, and product-identity risks remain.

what changes when the product is veterinary or underground?

a molecule's animal-drug authorization does not establish human formulation quality or use. concentration, ester identity, oil or suspension vehicle, sterility, endotoxin, particulates, and impurities become separate exposure risks on top of the pharmacology.

claim checks

related comparisons

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.